Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy
Authors' conclusion
Our results suggest an anti-atherogenic signature in the plasma metabolome after the first 6 months of feminizing GAHT, with cyproterone acetate also reducing specific plasma amino acids. This study provides novel insight into the metabolic changes occurring across feminizing GAHT.
Study context
- Population
- Transgender women starting feminizing gender-affirming hormone therapy (GAHT); plus an unrelated cohort of children and parents for sex- and age-related metabolite patternsparents 3,748
- Participants
- 53 women
- Comparison
- Cyproterone acetate vs spironolactone as anti-androgen in feminizing GAHT
- Primary endpoint
- Changes in 249 plasma metabolic biomarkers
- Follow-up
- Baseline, 3 and 6 months
Methodological detailslongitudinal, NMR-based metabolomics
- Longitudinal
- NMR-based metabolomics
Primary result
As reported in the abstract
Plasma metabolic biomarkers altered · 6 months
Biomarkers altered in both anti-androgen groups, mostly VLDL/LDL subclasses, all but 1 decreased
43
Biomarkers with the most abundant sex- and age-related pattern significantly lowered after GAHT, a shift toward the adult female profile
80%
Original publication
Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy. J Clin Endocrinol Metab. Published 13 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →